To date, four HDAC inhibitors, vorinostat, romidepsin, panobinostat, and belinostat, have been approved by the US Food and Drug Administration and are used for treating hematological cancers [45]. This evidence concerns the gene HDAC9 and hematopoietic and lymphoid cell neoplasm.